1. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France: a pooled analysis from Italy and France
- Author
-
Sormani, M. (Maria Pia) P. (P), Salvetti, M. (Marco), Labauge, P. (Pierre), Schiavetti, I. (Irene), Zephir, H. (Helene), Carmisciano, L. (Luca), Bensa, C. (Caroline), De Rossi, N. (Nicola), Pelletier, J. (Jean), Cordioli, C. (Cinzia), Vukusic, S. (Sandra), Moiola, L. (Lucia), Kerschen, P. (Philippe), Radaelli, M. (Marta), Théaudin, M. (Marie), Immovilli, P. (Paolo), Casez, O. (Olivier), Capobianco, M. (Marco), Ciron, J. (Jonathan), Trojano, M. (Maria), Stankoff, B. (Bruno), Créange, A. (Alain), Tedeschi, G. (Gioacchino), Clavelou, P. (Pierre), Comi, G. (Giancarlo), Thouvenot, E. (Eric), Battaglia, M. (Mario) A. (Alberto), Moreau, T. (Thibault), Patti, F. (Francesco), De Sèze, J. (Jérôme), Louapre, C. (Celine), and Musc
- Subjects
Aucun - Abstract
We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39-3.02, p
- Published
- 2021